在治疗耐药的转移性前列腺癌中,反复出现的免疫原性新抗原及其相关的T细胞受体
Nofar Gumpert1, Shira Sagie1, Claudia Arnedo-Pac2
1Weizmann Institute of Science, Rehovot, Israel.
Cancer discovery
|October 7, 2025
概括
研究人员开发了SpotNeoMet,以寻找治疗耐药癌症的新免疫治疗点. 这条管道确定了转移性割抵抗性前列腺癌的新型新抗原和T细胞受体,提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 耐治疗的转移性癌症需要新的治疗策略.
- 识别特定的新抗原对于开发有效的免疫疗法至关重要.
研究的目的:
- 开发一个数据驱动的管道 (SpotNeoMet) 用于识别治疗耐药癌症中的新抗原.
- 发现转移性割抵抗性前列腺癌 (mCRPC) 的新型免疫治疗点.
主要方法:
- 使用SpotNeoMet管道系统识别复发性新.
- 通过HLA-免疫组学来发现来自雄激素受体 (AR) 突变的新.
- 分离和表征相关的T细胞受体 (TCRs).
主要成果:
- 鉴定了7种治疗耐药性突变,预计会产生新.
- 在mCRPC中发现了三种由AR H875Y突变衍生而来的新.
- 验证了AR H875Y特定的TCR,以其在体外和体内杀死前列腺癌细胞的能力.
结论:
- 在SpotNeoMet管道中,成功地确定了新的免疫疗法点.
- 针对AR H875Y的特异性TCR显示出作为针对mCRPC的向治疗的潜力.
- 该管道提供了一种系统的方法,用于识别各种抗治疗癌症中的HLA-对和相关的TCR.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
12.4K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Diversity of Antigen Receptors
1.4K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.4K
